Jounce Therapeutics Inc Quick Ratio (JNCE) starting from the fourth quarter 2022 to fourth quarter 2021, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Jounce Therapeutics inc   (NASDAQ: JNCE)

Jounce Therapeutics Inc 's Quick Ratio

JNCE's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Jounce Therapeutics Inc 's Cash & cash equivalent grew by 47.38 % in the Q4 2022 sequentially, faster than Current Liabilities, this led to improvement in Jounce Therapeutics Inc 's Quick Ratio to 8.04, Quick Ratio remained below Jounce Therapeutics inc average.

Within Biotechnology & Pharmaceuticals industry 57 other companies have achieved higher Quick Ratio than Jounce Therapeutics Inc in fourth quarter 2022. While Quick Ratio total ranking has improved so far during the Q4 2022 to 520, from total ranking in the third quarter 2022 at 701.

Explain Quick Ratio?
How much Cash & cash equivalents JNCE´s has?
What are JNCE´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

JNCE Quick Ratio (Dec 31 2022)
Q4		 (Sep 30 2022)
Q3		 (Jun 30 2022)
Q2		 (Mar 31 2022)
Q1		 (Dec 31 2021)
Q4
Y / Y Current Liabilities Change 24.71 % 20.45 % 46.42 % 29.22 % -2.2 %
Y / Y Cash & cash equivalent Change 6.15 % -41.43 % -32.51 % -39.64 % -13.52 %
Quick Ratio MRQ 8.04 5.9 6.41 9.31 9.45
JNCE's Total Ranking # 520 # 701 # 649 # 707 # 252
Seq. Current Liabilities Change 8.12 % -6.03 % 38.88 % -11.62 % 4.43 %
Seq. Cash & cash equivalent Change 47.38 % -13.43 % -4.41 % -12.96 % -18.69 %



Quick Ratio fourth quarter 2022 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 58
Healthcare Sector # 271
Overall Market # 520


Quick Ratio Statistics
High Average Low
22.98 9.56 1.96
(Jun 30 2018)   (Jun 30 2019)




Financial Statements
Jounce Therapeutics Inc 's Current Liabilities $ 24 Millions Visit JNCE's Balance sheet
Jounce Therapeutics Inc 's Cash & cash equivalent $ 190 Millions Visit JNCE's Balance sheet
Source of JNCE's Sales Visit JNCE's Sales by Geography


Cumulative Jounce Therapeutics Inc 's Quick Ratio

JNCE's Quick Ratio for the trailling 12 Months

JNCE Quick Ratio

 (Dec 31 2022)
12 Months		 (Sep 30 2022)
12 Months		 (Jun 30 2022)
12 Months		 (Mar 31 2022)
12 Months		 (Dec 31 2021)
12 Months
Y / Y Current Liabilities TTM Growth 29.65 % 21.76 % 19.45 % 12.65 % 4.22 %
Y / Y Cash & cash equivalent TTM Growth -28.96 % -32.37 % -10.93 % 11.26 % 49.73 %
Quick Ratio TTM 7.3 7.58 9.13 11.13 13.32
Total Ranking TTM # 4203 # 4195 # 106 # 403 # 3899
Seq. Current Liabilities TTM Growth 5.79 % 4.81 % 10.58 % 5.74 % -0.64 %
Seq. Cash & cash equivalent TTM Growth 1.8 % -12.96 % -9.25 % -11.65 % -3.09 %

Quick ratio ranking by company, industry and sector >> Back to JNCE Financial Strength Comparisons >> Go to Compare JNCE Quick Ratio to its Competitors

On the trailing twelve months basis Due to rise in Current Liabilities in the Q4 2022 to $23.57 millions, cumulative Quick Ratio decreased to 7.3 above the JNCE average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 186 other companies have achieved higher Quick Ratio than Jounce Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2022 from 4195 to 4203.

Explain Quick Ratio?
How much Cash & cash equivalents JNCE´s has?
What are JNCE´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 187
Healthcare Sector # 1129
Within the Market # 4203


trailing twelve months Quick Ratio Statistics
High Average Low
13.65 6.83 2.49
(Sep 30 2021)   (Jun 30 2019)




Companies with similar Quick Ratio in the quarter ending Dec 31 2022, within Biotechnology & Pharmaceuticals Industry Quick RatioDec 31 2022 MRQ Cash & cash equivalentDec 31 2022 MRQ Current Liabilities
Hillevax Inc   21.42 $ 279.401  Millions$ 13.046  Millions
Vivosim Labs Inc   20.73 $ 28.675  Millions$ 1.383  Millions
Lenz Therapeutics Inc   20.56 $ 268.229  Millions$ 13.043  Millions
Genenta Science S p a   19.32 $ 33.370  Millions$ 1.727  Millions
Replimune Group Inc   19.06 $ 395.655  Millions$ 20.756  Millions
Prime Medicine Inc   19.05 $ 286.087  Millions$ 15.020  Millions
Aura Biosciences Inc   18.06 $ 188.831  Millions$ 10.457  Millions
Ginkgo Bioworks Holdings Inc   16.93 $ 1,315.792  Millions$ 77.709  Millions
Acumen Pharmaceuticals Inc   15.91 $ 177.605  Millions$ 11.162  Millions
Icosavax Inc   15.83 $ 218.307  Millions$ 13.788  Millions
Anavex Life Sciences Corp   15.27 $ 149.158  Millions$ 9.770  Millions
Apogee Therapeutics Inc   15.22 $ 151.890  Millions$ 9.980  Millions
Compugen Ltd  15.16 $ 83.708  Millions$ 5.523  Millions
Invivyd Inc   14.86 $ 371.991  Millions$ 25.031  Millions
Quince Therapeutics Inc   14.86 $ 45.602  Millions$ 3.069  Millions
Cardiff Oncology Inc   14.76 $ 105.267  Millions$ 7.133  Millions
Protara Therapeutics Inc  14.70 $ 84.370  Millions$ 5.740  Millions
Tarsus Pharmaceuticals Inc   14.07 $ 217.026  Millions$ 15.429  Millions
Neumora Therapeutics Inc   13.85 $ 371.884  Millions$ 26.859  Millions
Candel Therapeutics Inc   13.60 $ 70.058  Millions$ 5.151  Millions
Krystal Biotech Inc   13.14 $ 379.171  Millions$ 28.847  Millions
Lexeo Therapeutics Inc   12.97 $ 77.335  Millions$ 5.964  Millions
Fusion Pharmaceuticals Inc   12.54 $ 170.874  Millions$ 13.624  Millions
Century Therapeutics inc   12.40 $ 369.735  Millions$ 29.817  Millions
Rubius Therapeutics Inc   12.07 $ 14.865  Millions$ 1.232  Millions
Achilles Therapeutics Plc  11.76 $ 173.338  Millions$ 14.738  Millions
Crispr Therapeutics Ag  11.67 $ 1,815.318  Millions$ 155.508  Millions
Springworks Therapeutics Inc   11.60 $ 592.212  Millions$ 51.049  Millions
Compass Therapeutics Inc   11.54 $ 186.609  Millions$ 16.169  Millions
Cabaletta Bio Inc   11.23 $ 106.547  Millions$ 9.489  Millions

Date modified: 2026-09-18T13:11:05+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.